Answers are grounded in this paper and cite their sources.
Our results indicate that Pim overexpression enhances the invasive properties of prostate cancer cells in vivo. These effects can be reduced by the Pim-selective inhibitor DHPCC-9, which can reach tumor tissues without serious side effects. Thus, Pim-targeting therapies with DHPCC-9-like compounds may help to prevent progression of local prostate carcinomas to fatally metastatic malignancies.
No takes yet. Share an insight, caveat, or question.
Santio et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: